Drugs that contain Tesamorelin Acetate
1. Egrifta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5861379 | EMD SERONO | Chimeric fatty body-pro-GRF analogs with increased biological potency |
May, 2015
(8 years ago) | |
| US6020311 | EMD SERONO | GRF analogs with increased biological potency |
May, 2015
(8 years ago) | |
| US7144577 | EMD SERONO | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
Jul, 2020
(3 years ago) | |
| US8314066 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(9 months ago) | |
| US8435945 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(9 months ago) | |
| US7316997 | EMD SERONO | GH secretagogues and uses thereof |
Aug, 2023
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2015 |
NCE-1 date: 10 November, 2014
Market Authorisation Date: 10 November, 2010
Treatment: Reduction of excess abdominal fat in hiv-infected patients with lipodystrophy
Dosage: POWDER;SUBCUTANEOUS
More Information on Dosage
EGRIFTA family patents
